Alpha 2.0
Login Register
» Authors » Jacek Kociszewski

Jacek Kociszewski

Explore the profile of Jacek Kociszewski including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 31
Citations 196
Followers 0
Related Specialties
Gynecology & Obstetrics
General Medicine
Urology
Top 10 Co-Authors
Volker Viereck
Andrzej Kuszka
Oliver Rautenberg
Ewa Barcz
Grzegorz Surkont
Edyta Wlazlak
Aneta Zwierzchowska
Wojciech Majkusiak
Jakob Eberhard
Marianne Gamper
Published In
Neurourol Urodyn
J Ultrason
Int Urogynecol J
Ginekol Pol
Arch Gynecol Obstet
Affiliations
Soon will be listed here.
Recent Articles
1.
Correlation analysis of selected anatomical and functional parameters of the urethra, assessed through ultrasound and urodynamic examinations
Wojtowicz H, Wlazlak E, Kociszewski J, Wlazlak W, Krakowiak J, Fijolek-Wieclawek W, et al.
J Ultrason . 2025 Jan; 24(99):1-7. PMID: 39839502
Aim: This study aimed to examine the correlations between specific urethral function parameters observed in urodynamic testing and selected urethral characteristics evaluated by pelvic floor ultrasonography. Additionally, the presence of...
2.
Association analysis of ADRB3:rs4994 with urodynamic outcome, six months after a single intra-detrusor injection of botulinum toxin, in women with overactive bladder
Ciecwiez S, Lewandowska K, Szylinska A, Boron A, Kotlega D, Kociszewski J, et al.
Pharmacol Rep . 2024 Sep; 76(6):1489-1500. PMID: 39259490
Background: Intra-detrusor injection of botulinum neurotoxin type A (BoNT/A) is recommended as a possible treatment for patients with overactive bladder (OAB) in whom first-line therapies have failed. The c.190T > ...
3.
Current Treatment of Stress Urinary Incontinence by Bulking Agents and Laser Therapy-An Update
Sikora M, Gamper M, Zivanovic I, Munst J, Bischofberger H, Kociszewski J, et al.
J Clin Med . 2024 Apr; 13(5). PMID: 38592248
Stress urinary incontinence (SUI) affects around 20% of women. In addition to the established suburethral sling insertion, two less invasive approaches are of interest today: urethral bulking agents and vaginal...
4.
Diagnosis and Therapy of Female Urinary Incontinence. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/091, January 2022): Part 1 with Recommendations on Diagnostics and Conservative and Medical Treatment
Naumann G, Aigmuller T, Bader W, Bauer R, Beilecke K, Betschart Meier C, et al.
Geburtshilfe Frauenheilkd . 2023 Apr; 83(4):377-409. PMID: 37034417
This completely revised interdisciplinary S2k-guideline on the diagnosis, therapy, and follow-up care of female patients with urinary incontinence (AWMF registry number: 015-091) was published in December 2021. This guideline combines...
5.
Diagnosis and Therapy of Female Urinary Incontinence. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 015/091, January 2022): Part 2 with Recommendations on Interventional/Surgical Therapy of Overactive Bladder, Surgical...
Naumann G, Aigmuller T, Bader W, Bauer R, Beilecke K, Betschart Meier C, et al.
Geburtshilfe Frauenheilkd . 2023 Apr; 83(4):410-436. PMID: 37034416
This completely revised interdisciplinary S2k-guideline on the diagnosis, therapy, and follow-up care of female patients with urinary incontinence (AWMF registry number: 015-091) was published in December 2021. This guideline combines...
6.
Functional Polymorphism in the Gene, Encoding the Beta-3 Adrenergic Receptor, and Response to Intra-Detrusor Injection of Botulinum Toxin-A in Women with Overactive Bladder
Ciecwiez S, Lewandowska K, Boron A, Brodowski J, Kociszewski J, Clark J, et al.
J Clin Med . 2022 Dec; 11(24). PMID: 36556105
Background: There are reports suggesting an association between the rs4994 polymorphism in the gene encoding the beta-3 adrenergic receptor and OAB risk in females. The injection of botulinum toxin-A into...
7.
Atrial fibrillation during pregnancy: a 9-month period with limited options
Iliodromitis K, Kociszewski J, Bogossian H
Herzschrittmacherther Elektrophysiol . 2021 Apr; 32(2):158-163. PMID: 33822238
Pregnancy is a physiological condition with reversible hemodynamic, neurohormonal and coagulation changes to the maternal body during this 9‑month period. The occurrence of atrial fibrillation (AF) is altogether rare among...
8.
How to balance the treatment of stress urinary incontinence among female athletes?
Rzymski P, Burzynski B, Knapik M, Kociszewski J, Wilczak M
Arch Med Sci . 2021 Mar; 17(2):314-322. PMID: 33747266
Urinary incontinence in the general population occurs in 7% of non-pregnant women under 39 years old, 17% of those 40 to 59 years old, and 23-32% of those over 60...
9.
Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways
Wrobel A, Serefko A, Wozniak A, Kociszewski J, Szopa A, Wisniewski R, et al.
Pharmacol Biochem Behav . 2020 Jan; 189:172842. PMID: 31899220
Though the association between overactive bladder (OAB) and depression was noticed years ago, the pharmaceutical market does not offer one universal drug that would cure both conditions at the same...
10.
Erbium:YAG laser treatment of female stress urinary incontinence: midterm data
Kuszka A, Gamper M, Walser C, Kociszewski J, Viereck V
Int Urogynecol J . 2019 Dec; 31(9):1859-1866. PMID: 31828400
Introduction And Hypothesis: Stress urinary incontinence (SUI) is treated using intravaginal laser therapy. We wanted to find out how incontinence severity at baseline and the number of laser interventions affect...